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Development of lymphocytes is precisely regulated by various mechanisms. In addition to
transcriptional rates, post-transcriptional regulation of mRNA abundance contributes to
differentiation of lymphocytes. mRNA decay is a post-transcriptional mechanism
controlling mRNA abundance. The carbon catabolite repression 4 (CCR4)-negative on
TATA-less (NOT) complex controls mRNA longevity by catalyzing mRNA deadenylation,
which is the rate-limiting step in the mRNA decay pathway. mRNA decay, regulated by the
CCR4-NOT complex, is required for differentiation of pro-B to pre-B cells and V(D)J
recombination in pro-B cells. In this process, it is likely that the RNA-binding proteins,
ZFP36 ring finger protein like 1 and 2, recruit the CCR4-NOT complex to specific target
mRNAs, thereby inducing cell quiescence of pro-B cells. A recent study showed that the
CCR4-NOT complex participates in positive selection of thymocytes. Mechanistically,
the CCR4-NOT deadenylase complex inhibits abnormal apoptosis by reducing the
expression level of mRNAs encoding pro-apoptotic proteins, which are otherwise up-
regulated during positive selection. We discuss mechanisms regulating CCR4-NOT
complex-dependent mRNA decay in lymphocyte development and selection.
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Pleiotropic mechanisms control cytoplasmic mRNA abundance. Besides transcriptional regulation,
post-transcriptional mechanisms are critical for controlling the level of cytoplasmic mRNA. mRNA
decay is a post-transcriptional mechanism for reducing mRNA abundance. One major role of
mRNA decay systems is to control homeostatic turnover and quality of mRNA. In addition, mRNA
decay pathways actively regulate mRNA abundance, which is necessary to maintain and alter
mRNA quantity in response to physiological signals. Many studies have suggested that active
regulation of mRNA decay mechanisms must be critical for immune regulation and homeostasis
(1–14). In this review, we focus on functions of the mRNA decay system regulated by the carbon
catabolite repression 4 (CCR4)-negative on TATA-less (NOT) deadenylase complex in early
lymphocyte development.org July 2021 | Volume 12 | Article 7156751
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Functionally, mRNA decay comprises two classes. The first is the
mRNA decay system required for RNA surveillance to prevent
generation of potentially toxic proteins (15). Nonsense-mediated
mRNA decay (NMD) is an mRNA quality control pathway that
degrades aberrant mRNAs with premature termination codons
(16–18). In addition, No-go decay and No-stop decay pathways
lead to mRNA decay in cases of ribosome stalling due to
accidental blockades of translation and failure of termination,
respectively (19).
The second class is the mRNA decay system that actively
regulates amounts of mRNA encoding functional proteins.
Exonuclease and endonuclease mRNA decay pathways mainly
contribute to this “active”mRNA decay (14, 16, 20). In addition,
some recent studies have proposed involvement of the NMD
mechanism in regulation of mRNAs encoding full-length
proteins during embryonic development and tissue-specific cell
differentiation (18, 21).INITIATION OF THE mRNA DECAY
PATHWAY BY DEADENYLATION
The exonuclease pathway of mRNA decay is initiated by
removing polyA tails from mRNAs (16, 20). Following
deadenylation of polyA tails, the 5’ cap structure of
deadenylated mRNAs is removed by recruiting the decapping
complex (Dcp1/Dcp2). Then 5’-3’ exoribonuclease 1 and 2
degrade decapped mRNAs from their 5′ ends.
Deadenylation of mRNA is the rate-limiting step for the
exonuclease pathway. At present, three deadenylases have been
reported: carbon catabolite repressor 4-negative on the TATA
(CCR4-NOT) complex, polyA nuclease 2 (Pan2)-Pan3, and
polyA-specific ribonuclease (PARN) (16, 20). A previous study
suggested that cytoplasmic deadenylase activity of the CCR4-
NOT complex predominated (22). In contrast, PAN2/3 trims
relatively long tails of polyA (above 150 nt) and exerts minimal
influence on the transcriptome.
In humans and mice, The CCR4-NOT complex is composed
of eight protein subunits (23–25). CCR4-NOT transcription
complex subunit 1 (CNOT1) serves as a scaffold to assemble
the other subunits and recruits RNA-binding proteins (26–28).
Two subunits, CNOT6/6L and CNOT7/8, have deadenylase
activity (29–32). Other CNOT subunits (CNOT2, 3, 9,10, and
11) lack deadenylase activity and may regulate catalytic functions
of the complex (6, 33, 34). Individual deletion of CNOT2,
CNOT3 and CNOT10 destabilized the complex and caused
degradation of other subunits (6, 33, 34). Thus, these CNOT
subunits evidently also contribute to the integrity of the whole
CCR4-NOT complex. In addition, CNOT2 and CNOT3 form a
heterodimer that recruits RNA-binding proteins to the CCR4-
NOT complex (35, 36). Moreover, in vitro reconstitution
experiments showed that the CNOT2-CNOT3 heterodimer
maximizes the deadenylase activity and poly (A) selectivity of
the CCR4-NOT complex (37).Frontiers in Immunology | www.frontiersin.org 2Ablation of genes encoding individual subunits of the CCR4-
NOT complex revealed its roles in various physiological
functions. For instance, CNOT3 is required for postnatal liver
functions (38), pancreatic b cell function and identity (39),
maintaining cardiac homeostasis (40), and bone resorption
(41). CNOT7, a catalytic subunit, has non-redundant functions
in spermatogenesis (42, 43). In addition, some studies showed a
requirement of deadenylation induced by the CCR4-NOT
complex in early lymphocyte development (3, 4, 6).FUNCTIONS OF THE CCR4-NOT
COMPLEX IN LYMPHOCYTE
DEVELOPMENT
Early B cell differentiation has been widely studied (44, 45). Pro-
B cells derived from common progenitor cells differentiate into
pre-B cells and subsequently immature B cells. In the transition
of pro-B cells to pre-B cells, generation of the immunoglobulin
(Ig) m heavy chain assembled from variable (VH), diversity (DH),
and joining (JH) gene segments in pro-B cells is essential.
Together with surrogate light chains, Igm heavy chains form a
precursor B cell receptor (pre-BCR). Pre-BCR signaling
terminates the V(D)J recombination and induces rapid
proliferation. After quiescence is re-established by later
signaling from pre-BCR, recombination of light chains occurs
for further differentiation of pre-B cells into immature B cells.
In B cell development, CNOT3 protein is up-regulated during
differentiation from pro-B cells to pre-B cells (3). Two studies
reported a requirement for CNOT3 in B cell development (3, 4).
Inoue et al. (3) showed that B cell-specific deletion of Cnot3 in
mice withMbl1-Cre deleter resulted in a severe reduction of pre-
B cell differentiation thereafter. Moreover, rearrangements
resulting from joining of distal variable gene segments of the Ig
heavy chain (Igh) gene (VH) to its diversity and joining (DH JH)
gene segments were impaired, although the proximal VH to DH
JH rearrangement and DH to JH rearrangement were not affected.
Mechanist ical ly , the CCR4-NOT complex mediates
deadenylation of Trp53 mRNA coding p53 protein, reducing
its transcript level in pro-B cells. Cnot3 deletion caused up-
regulation of p53, thereby causing an increase in the expression
level of pro-apoptotic genes regulated by p53. Interestingly,
deletion of the p53 gene partially rescued the defect of pro-B
cell differentiation due to the CNOT3 deficiency, but it did not
rescue the failure of the distal VH to DH JH rearrangement. Thus,
CCR4-NOT complex-mediated RNA decay ensures gene
rearrangement in pro-B cells through p53-independent
mechanisms and prevents abnormal apoptosis in both p53-
dependent and independent mechanisms during the pro-B cell
to pre-B cell transition (Figure 1).
Yang et al. also reported a defect in the transition from pro-B
cells to pre-B cells due to deletion of the Cnot3 gene (4). Because
Cnot3-deletion throughout the body causes embryonic lethality,
the tamoxifen-inducible Cre-driver mouse strain in addition to
Mbl1-Cre mice was used. Even though both mouse lines showed
pro-B cell arrest, the effect was more severe in the Cnot3 deletionJuly 2021 | Volume 12 | Article 715675
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from excess nuclear accumulation of CRE protein, driven by the
Mbl1-promoter. Notably, CNOT3 interacts with Early B-cell
factor 1 (EBF1), which is critical for establishing B cell
lineages. Mutation of a histidine residue in the DNA-binding
domain (DBD) of EBF1 abolished its binding to CNOT3.
Moreover, transduction of DBD mutant protein rescued the
differentiation defect of EBF1-deficient B progenitors less
efficiently in vitro compared to wild-type protein, suggesting
that the interaction between CNOT3 and EBF1 is critical for B
cell differentiation. Thus, the CCR4-NOT complex may function
in both mRNA decay and transcription in pro-B cell
differentiation. However, it is still not clear whether these two
events are coupled and whether they influence each other.
Early development of conventional T cells occurs in the
thymus (46). Briefly, T cell progenitors from bone marrow
differentiate into CD4–CD8– (DN) thymocytes. In the DN
thymocyte stage, recombination of TCRb chain genes and their
selection occurs. DN thymocytes then differentiate into
CD4+CD8+ (DP) thymocytes. After completing TCRa chain
recombination, DP thymocytes undergo positive selection to
test the quality and specificity of the TCR ab complex.
Positively selected DP thymocytes differentiate into CD4 or
CD8 single-positive (SP) cells. In the process of positive
selection, DP and SP thymocytes are further separated by
expression levels of surface CD3 and CD69 (47). Before
positive selection, DP thymocytes express low levels of CD69
and CD3. During positive selection, CD3 and CD69 expressionFrontiers in Immunology | www.frontiersin.org 3are up-regulated by TCR signaling. After completion, the
expression level of CD3 persists, but surface CD69 expression
is down-regulated.
A recent study revealed the activity of the CCR4-NOT
complex in positive selection (Figure 1). In thymic T cell
development, some protein subunits of the CCR4-NOT
complex (CNOT1, 2, 3 and 6) are up-regulated in the
transition from DN thymocytes to DP thymocytes (6). T-cell-
specific deletion of the murine Cnot3 gene by the CD4-Cre
deleter caused a severe developmental defect of CD4 and CD8SP
thymocytes in the thymus. Specifically, the Cnot3 deletion caused
a severe reduction of CD69hiCD3hi cells and CD69loCD3hi cells,
but did not influence pre-selected CD69loCD3int thymocytes,
suggesting that the CCR4-NOT complex is required during
positive selection. mRNAs encoding pro-apoptotic molecules,
DAB2-interacting protein (DAB2IP) (48) and BCL2-binding
component 3 (BBC3) (49), were up-regulated and their polyA
tails were elongated in Cnot3-deficient thymocytes during the
course of positive selection. Moreover, transduction of anti-
apoptotic Bcl-2 protein into Cnot3-deficient bone marrow
progenitor cells rescued the developmental defect of
thymocytes caused by Cnot3-deletion. Thus, by trimming their
polyA tails, the CCR4-NOT complex promotes degradation of
mRNAs encoding these pro-apoptotic proteins, which are up-
regulated during positive selection. This regulation by the CCR4-
NOT complex is necessary to prevent abnormal apoptosis during
positive selection. Interestingly, up-regulation of Dab2ip
resulting from Cnot3 deletion occurred in the CD69loCD3intFIGURE 1 | Early lymphocyte development regulated by the CCR4-NOT complex. The CCR4-NOT complex is required for differentiation of pro-B cells to pre-B
cells and positive selection of DP thymocytes. ZFP36L1 and ZFP36L2 (ZFP36L1/2) regulate the pro-B cell to pre-B cell transition and b-selection of the DN3
thymocyte stage. Involvement of the CCR4-NOT complex in b selection has not been verified yet. Some differentiation stages were omitted for simplicity. CLP,
common lymphoid progenitor; DN, CD4 CD8 double negative thymocyte; DP, CD4 CD8 double positive thymocyte; SP, CD4 or CD8 single positive thymocytes.July 2021 | Volume 12 | Article 715675
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contrast, Bbc3 was up-regulated from the CD69hiCD3hi stage in
the absence of CNOT3. Thus, the CCR4-NOT complex may
prevent thymocyte apoptosis during two distinct stages of
positive selection via two different mechanisms.UPSTREAM EVENTS LEADING TO CCR4-
NOT-MEDIATED RNA DEGRADATION
Several mechanisms reportedly trigger RNA decay by recruiting
the CCR4-NOT complex to target mRNAs (Figure 2). ZFP36
family proteins, including ZFP36, ZFP36 ring finger protein-like
(ZFP36L) 1 and ZFP36L2, bind to specific sequences in 3’
untranslated regions (UTRs) of mRNAs (50, 51). The CCR4-
NOT complex is recruited by ZFP36L1 and ZFP36L2 (28), and
initiates deadenlyation of mRNAs bound to ZFP36L1 and
ZFP36L2, thereby promoting decay of targeted mRNAs. B cell-
specific deletion of both Zfp36l1 and Zfp36l2 genes caused a
severe reduction of cellularity from the pre-B cell stage onward
(5). Furthermore, Igm chain expression in pro-B and early pre-B
cells was reduced in these mutant mice. Thus, ZFP36L1 or
ZFP36L2 is required for differentiation of pro-B cells into pre-
B cells and recombination of Igh in early B cells (Figure 1).
Notably, phenotypes of these mutant mice were quite similar to
those of B-cell-specific Cnot3-deficient mouse lines.
Transcriptome analysis of late pre-B cells in Zfp36l1 and
Zfp36l2 doubly-deficient mice showed an increase in the
expression level of several cell-cycle related genes. Consistently,
cell cycle analysis showed that pro-B cells in S phase wereFrontiers in Immunology | www.frontiersin.org 4significantly increased and that those in G0 phase were
severely reduced by depletion of ZFP36L1 and ZFP36L2.
Progression of V(D)J recombination requires cellular
quiescence because expression of RAG2 protein is restricted to
G0 and G1 phase (52–55). Thus, ZFP36L1 and ZFP36L2
redundantly suppress cell cycle progression in early B cell
stages via degradation of mRNAs encoding cell cycle-related
genes, which may be required to promote V(D)J recombination.
Putative target mRNAs of ZFP36L1 were upregulated in Cnot3-
deficient pro-B cells (3). In addition, as described, CNOT3
deficiency resulted in failure of V(D)J recombination in pro-B
cells in a p53-independent manner (3). Overall, these findings
suggest that ZFP36L1 or ZFP36L2 recruits the CCR4-NOT
complex and leads to degradation of mRNAs encoding cell
cycle-promoting genes, thereby regulating cell cycle entry and
exit to promote progression of V(D)J recombination. Because
Zfp36l1 and Zfp36l2 genes are expressed throughout B cell
development, there may be up-stream events activating
ZFP36L1 and ZFP36L2, or promoting recruitment to their
target mRNAs.
In addition to B cell development, ZFP36L1 and ZFP36L2
regulate early T cell differentiation. As in B cells, Zfp36l1 and
Zfp36l2 genes are expressed throughout thymocyte development.
Mice in which both ZFP36L1 and ZFP36L2 were depleted in
early T cell progenitors developed T cell acute lymphoblastic
leukemia (56). Importantly, V(D)J recombination of TCRb gene
was defective in DN thymocytes of these doubly-deficient mice.
Thus, DN thymocytes in mutant mice by-pass the b-selection
checkpoint without expression of TCRb and are converted into T
lymphoblasts. Mechanistically, the ZFP36L1- and ZFP36L2-FIGURE 2 | Active RNA decay pathways mediated by the CCR4-NOT complex. The CCR4-NOT complex can be recruited by RNA binding proteins (RBP), miRNA-
Ago2 complex, and YTHDF2 bound to N6-methyladeonsine, which is generated by the METTL3 and METTL14 methyltransferase complexes. The CCR4-NOT
complex deadenylates polyA tails of recruited mRNAs. After deadenylation, 5’-decapping enzymes are recruited and eliminate the cap structure. Finally, 5’-
exonucleases (Xrn1 and 2) causes degradation of target mRNAs.July 2021 | Volume 12 | Article 715675
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regulation of genes involved in DNA damage-response and cell
proliferation (57). This suppression appeared crucial to induce
cellular quiescence required for V(D)J recombination in DN
thymocytes. Considering that V(D)J recombination occurs in
both DN thymocytes and pro-B cell stages, functions of ZFP36L1
and ZFP36L2 may be similar in these two cell types (Figure 1).
Although this may imply a requirement for CCR4-NOT
complex-dependent RNA decay in the DN stages, involvement
of the CCR4-NOT complex in V(D)J recombination of DN
thymocytes has not been addressed yet.
Roquin family proteins, ROQUIN-1 and ROQUIN-2, can
also recruit the CCR4-NOT complex in the 3’-UTRs of target
mRNAs (58). T cell-specific deletion of both Rc3h1 and Rc3h2
(encoding ROQUIN-1 and ROQUIN-2, respectively) genes
resulted in enhanced helper T cell activation and follicular
helper T cell differentiation with spontaneous inflammation
(10). Puzzlingly, these phenotypes have not been observed in
T-cell-specific Cnot3-deficient mice. However, because T-cell-
specific deletion of Cnot3 severely impaired mature T cell
development in the thymus, the phenotype that characterized
the later T cell stage needs to be clarified. Alternatively, other
mRNA decay systems may function downstream of these
ROQUIN family proteins.
Among epigenetic modifications of mRNA, the N6-methyl
adenosine (m6A) modification in RNA is intensively studied (59,
60). Them6Amodification is recognized by the YT521-B homology
domain-containing family 2 that recruits the CCR4-NOT complex
(61) (Figure 2). Thus, m6A modification can lead to CCR4-NOT
complex-mediated RNA decay. The N6-methylation of adenosine is
catalyzed by methyl transferase (METTL) 3 and METTL14
complexes (62). CD4-Cre-mediated deletion of the Mettl3 gene
suppressed homeostatic proliferation of peripheral CD4-positive T
cells under lymphopenic conditions (63). Socs mRNA degradation
induced by interleukin 7-signaling, which is required for
proliferation and differentiation of naïve T cells, was impaired in
these mice. Notably, again, the link between m6A modification and
CCR4-NOT complex-mediated mRNA decay is still obscure in T
cells because of the severe reduction of mature naive T cells in T cell-
specific Cnot3-deficient mice.
miRNAs form complexes with Argonaute family proteins on
their target sequences (64, 65). The miRNA- Argonaute family
complex recruits the CCR4-NOT complex or the PAN2-PAN3
complex, leading to degradation of target mRNAs (64, 65).
Conditional depletion of Dicer, an enzyme critical for miRNA
generation (66) in early B cells inhibited the transition of pro-B to
pre-B cells, suggesting a requirement of miRNA for this
differentiation stage (67). This phenotype is similar to that in
mice deficient for CNOT3. However, the Dicer deficiency did not
impair the V(D)J recombination reaction, whereas generation of
an antibody repertoire was disturbed (67). Thus, the miRNA-
CCR4-NOT complex axis in early B cells still needs to be clarified.
Although deletion of the Dicer gene in early thymocytes by
the Lck-Cre deleter caused a severe reduction in cellularity of
thymocytes, the percentage of each thymocyte fraction was not
affected (68). Moreover, Dicer deletion by CD4-Cre showedFrontiers in Immunology | www.frontiersin.org 5normal thymocyte number and percentages of thymocyte
subsets (69). Overall, miRNA-dependent mRNA decay through
recruitment of the CCR4-NOT complex might not be essential
for early thymocyte development and selection.CONCLUDING REMARKS
Rapid, simultaneous and dynamic transcription of several
mRNAs occurs during cell differentiation for generation of
functional proteins. In addition, protein abundance must be
precisely regulated to avoid deleterious cellular consequences.
Regulation of mRNA levels should be an efficient way to control
protein expression levels because one mRNA molecule generates
about 3000 protein molecules on average in mammalian cells
(70). However, once proteins are produced, RNA decay
mechanisms should be less effective than direct protein
degradation for regulating protein levels. Accordingly, it is
likely that RNA decay-dependent regulation of protein
concentrations by the CCR4-NOT complex is most effective
when cells receive signals initiating production of large numbers
of mRNA transcripts, such as during lymphocyte development.
It is likely that ZFP36L family proteins recruit the CCR4-NOT
complex to suppress cell-cycle-related genes and DNA damage-
responsive genes during early lymphocyte differentiation. In
contrast, upstream events of CCR4-NOT complex-dependent
regulation of thymic positive selection remain unknown.
Moreover, possible upstream mechanisms of the CCR4-NOT
complex, i.e., ROQUIN family, m6A modification, are necessary
to regulate differentiation and functions of lymphocytes in later
differentiation stages. Therefore, it is also important to address
whether CCR4-NOT complex-induced RNA decay controls these
lymphocyte differentiation and functions.
Finally, given that recent studies on human disease
progression and onset by dysregulation of RNA decay systems
(71–74), understanding RNA decay mechanisms would be
beneficial for developing therapies and preventive measures
against such diseases.AUTHOR CONTRIBUTIONS
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